FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if an imaging solution,
[F-18]-fluoro-L-thymidine (FLT), when used with a positron emission tomography (PET) scan,
can help doctors to better see changes in the growth of tumors in the body. Researchers want
to learn if FLT-PET scans can show an early response to chemotherapy.